RADBIO USA

RADBIO is a biotech company founded in 2018 by experienced scientists and entrepreneurs, designing and developing a novel biomolecule that neutralizes TGF-β, as a therapeutic for fibrotic diseases and solid tumors with unmet medical needs... TGF-β is a well validated target known as the "master regulator of fibrosis". We aim at harnessing the potential application of our biomolecule in several indications where TGF-β isoforms are upregulated.

Also known as: RADBIO, RADBIO USA, Inc.

Primary location: Wilmington United States